Evidence map›Paper›PMID 24789780›Full record

ArticleJournal of virology2014

Mechanistic differences between nucleic acid chaperone activities of the Gag proteins of Rous sarcoma virus and human immunodeficiency virus type 1 are attributed to the MA domain.

Tiffiny D Rye-McCurdy, Shorena Nadaraia-Hoke, Nicole Gudleski-O'Regan, John M Flanagan, Leslie J Parent, Karin Musier-Forsyth

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in Journal of virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. HIV-1 Pr55RNA biology · 2017
    Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Tiffiny D Rye-McCurdyThe Ohio State University, Department of Chemistry and Biochemistry, The Ohio State Biochemistry Program, Center for Retroviral Research, and Center for RNA Biology, Columbus, Ohio, USA.
Shorena Nadaraia-HokeDepartment of Microbiology and Immunology, Penn State College of Medicine, Hershey, Pennsylvania, USA Department of Medicine, Division of Infectious Diseases and Epidemiology, Penn State College of Medicine, Hershey, Pennsylvania, USA.
Nicole Gudleski-O'ReganDepartment of Microbiology and Immunology, Penn State College of Medicine, Hershey, Pennsylvania, USA.
John M FlanaganDepartment of Biochemistry and Molecular Biology, Penn State College of Medicine, Hershey, Pennsylvania, USA.
Leslie J ParentDepartment of Microbiology and Immunology, Penn State College of Medicine, Hershey, Pennsylvania, USA Department of Medicine, Division of Infectious Diseases and Epidemiology, Penn State College of Medicine, Hershey, Pennsylvania, USA.
Karin Musier-ForsythThe Ohio State University, Department of Chemistry and Biochemistry, The Ohio State Biochemistry Program, Center for Retroviral Research, and Center for RNA Biology, Columbus, Ohio, USA musier@chemistry.ohio-state.edu.
Penn State Milton S. Hershey Medical Center · USThe Ohio State University · US

Funding

Nuclear Trafficking of the Retroviral Gag ProteinR01CA076534 · NCI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI PARENT, LESLIE J · 1998 to 2018
$5.2M
RNA Binding and Packaging By Retroviral Gag ProteinsR01GM065056 · NIGMS · UNIVERSITY OF MINNESOTA TWIN CITIES · PI MUSIER-FORSYTH, KARIN M · 2002 to 2018
$4.9M
VIRUSES AND CANCERT32CA060395 · NCI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI MEYERS, CRAIG M · 1994 to 2021
$4.3M
CHEMISTRY/BIOLOGY TRAINING GRANTT32GM008512 · NIGMS · OHIO STATE UNIVERSITY · PI PEI, DEHUA · 1996 to 2016
$3.9M
NCI NIH HHS R01 CA076534NCI NIH HHS T32 CA060395NIGMS NIH HHS R01 GM065056NIGMS NIH HHS T32 GM008512NIGMS NIH HHS T32-GM008512
6 · The paper itself

Abstract

Host cell tRNAs are recruited for use as primers to initiate reverse transcription in retroviruses. Human immunodeficiency virus type 1 (HIV-1) uses tRNA(Lys3) as the replication primer, whereas Rous sarcoma virus (RSV) uses tRNA(Trp). The nucleic acid (NA) chaperone function of the nucleocapsid (NC) domain of HIV-1 Gag is responsible for annealing tRNA(Lys3) to the genomic RNA (gRNA) primer binding site (PBS). Compared to HIV-1, little is known about the chaperone activity of RSV Gag. In this work, using purified RSV Gag containing an N-terminal His tag and a deletion of the majority of the protease domain (H6.Gag.3h), gel shift assays were used to monitor the annealing of tRNA(Trp) to a PBS-containing RSV RNA. Here, we show that similar to HIV-1 Gag lacking the p6 domain (GagΔp6), RSV H6.Gag.3h is a more efficient chaperone on a molar basis than NC; however, in contrast to the HIV-1 system, both RSV H6.Gag.3h and NC have comparable annealing rates at protein saturation. The NC domain of RSV H6.Gag.3h is required for annealing, whereas deletion of the matrix (MA) domain, which stimulates the rate of HIV-1 GagΔp6 annealing, has little effect on RSV H6.Gag.3h chaperone function. Competition assays confirmed that RSV MA binds inositol phosphates (IPs), but in contrast to HIV-1 GagΔp6, IPs do not stimulate RSV H6.Gag.3h chaperone activity unless the MA domain is replaced with HIV-1 MA. We conclude that differences in the MA domains are primarily responsible for mechanistic differences in RSV and HIV-1 Gag NA chaperone function. Importance: Mounting evidence suggests that the Gag polyprotein is responsible for annealing primer tRNAs to the PBS to initiate reverse transcription in retroviruses, but only HIV-1 Gag chaperone activity has been demonstrated in vitro. Understanding RSV Gag's NA chaperone function will allow us to determine whether there is a common mechanism among retroviruses. This report shows for the first time that full-length RSV Gag lacking the protease domain is a highly efficient NA chaperone in vitro, and NC is required for this activity. In contrast to results obtained for HIV-1 Gag, due to the weak nucleic acid binding affinity of the RSV MA domain, inositol phosphates do not regulate RSV Gag-facilitated tRNA annealing despite the fact that they bind to MA. These studies provide insight into the viral regulation of tRNA primer annealing, which is a potential target for antiretroviral therapy.

Indexed as

Electrophoretic Mobility Shift Assaygag Gene Products, Human Immunodeficiency VirusGene Products, gagHIV-1HIV AntigensHumansMolecular ChaperonesPhosphoproteinsRNA, Transfer, TrpRNA, ViralRous sarcoma virusViral Matrix Proteinsgag Gene Products, Human Immunodeficiency VirusGene Products, gagHIV AntigensMA protein, Rous sarcoma virusMolecular Chaperonesp17 protein, Human Immunodeficiency Virus Type 1PhosphoproteinsRNA, Transfer, TrpRNA, ViralViral Matrix Proteins

Identifiers

PMID24789780
PMCPMC4097784
OpenAlexW2070881543

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.